Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma

Bookmark and Share
Published: 22 Jun 2021
Views: 935
Rating:
Save
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA

Dr Nilanjan Ghosh speaks to ecancer in an online interview for the virtual EHA 2021 meeting on the tolerability and efficacy results from a dose-escalation study of mosunetuzumab with polatuzumab vedotin for relapsed/refractory b-cell non-Hodgkin’s lymphoma.

He reports that the side effect profile was very manageable with 50% of patients experiencing Grade 3 or 4 adverse events and with CRS incidents experienced for 9.1%

Dr Ghosh also reported that the combination was very effective, with the overall response rate for all patients at 68% and the complete response rate at 55%.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
 

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.